Other languages RespireRx Pharmaceuticals Inc.

Equities

RSPI

US7612273059

Market Closed - OTC Markets Other stock markets 03:57:30 2024-05-21 pm EDT			5-day change	1st Jan Change
0.0008 ^USD	-11.11%		-20.00%	-11.11%

Apr. 10	RespireRx Pharmaceuticals Inc. announced that it has received $0.1 million in funding	CI
Mar. 20	RespireRx Pharmaceuticals Inc. Reports Publication of Preclinical Research Results Demonstrating the Ability of CX1739, its Lead Clinical AMPAkine, to Improve Bladder Function After Spinal Cord Injury	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

RespireRx Pharmaceuticals Inc. Reports Publication of Preclinical Research Results Demonstrating the Ability of CX1739, its Lead Clinical AMPAkine, to Improve Bladder Function After Spinal Cord Injury	Mar. 20
RespireRx Pharmaceuticals Inc. Reports Preclinical Pain Relief for Their Non-Opioid Lead GABAkine	Feb. 13
RespireRx Pharmaceuticals Inc. Announces the Appointment of Dariusz Naziek to its Board of Directors	Jan. 22
Respirerx Pharmaceuticals Inc. Announces the Publication of A Case Report in Which KRM-II-81 Totally Suppressed Epileptiform Activity in Brain Tissue Surgically Removed from Epileptic Patient	Jan. 04
RespireRx Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 17
RespireRx Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-21
RespireRx Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-22
RespireRx Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-17
RespireRx Pharmaceuticals Inc. Auditor Raises 'Going Concern' Doubt	23-04-16
RespireRx Pharmaceuticals Inc. Establishes Research Collaboration With University College London to Study the Use of AMPAkines for the Treatment of GRIA Disorders	23-04-05
RespireRx Pharmaceuticals Inc. Discloses Novel Structural Analogs of its GABAA Receptor Potentiator, KRM-II-81 with Antiseizure Efficacy and Antitremor Effects Without Sedation	23-04-03
Respirerx Pharmaceuticals Inc. Announces Appointment of Joseph Siegelbaum as Independent Member of the Board of Directors	23-03-28
ResolutionRx Ltd and RespireRx Pharmaceuticals Inc. Announce ResolutionRx’s Entry into a Services Agreement with iNGENu CRO Pty Ltd	23-03-01
RespireRx Pharmaceuticals Inc. Establishes ResolutionRx Ltd in Australia to Develop Its Pharmaceutical Cannabinoid Platform	23-01-12
RespireRx Pharmaceuticals Inc. Enters a Collaboration With National Institute for Neurological Disorders and Stroke to Advance its Lead GABAkine Toward Clinical Development	22-12-05
RespireRx Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-17
RespireRx Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-22
RespireRx Pharmaceuticals Inc. Announces Board Changes	22-08-03
RespireRx Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-23
RespireRx Pharmaceuticals Inc. Announces the Publication of a Review Article Highlighting the Potential Use of Gabakine Neuromodulators for the Treatment of Tinnitus	22-05-16

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages RespireRx Pharmaceuticals Inc.

Equities

RSPI

US7612273059

Other languages

Filters